Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing Disease Aggravation in COVID-19 by High-Dose Vitamin D (COVIT-D)
2020-001793-30Phase 4Terminated
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing High-dose vitamin D3 with Placebo (2 arms). Primary endpoint: Disease aggravation (DAOH within 6 weeks). Started May 2020; status: terminated.
02
Drugs
vitamin d
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001793-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001793-30.